Sygnature Discovery partners the Oncology Development Programme (ODP2) to find UK-based breakthroughs in Oncology
Sygnature Discovery joins four of the top ten global pharma companies, Cancer Research Horizons, Manchester Cancer Research Centre (MCRC) and over 20 Contract Research Organisations (CROs) to support innovation in oncology through the second Oncology Development Programme (ODP2). The initiative aims to accelerate development of high impact novel cancer innovations with delivery of the programme overseen by Lean Life Science.
Sygnature Discovery will partner the second Oncology Development Programme (ODP2)
UK-based academics and early-stage companies with a defined oncology-focused innovation can apply to participate in the programme, gaining access to bespoke expert scientific review, clinical study design, technical gap analysis, financial/business value modelling and integrated project planning. Applications began in late November with a Programme Faculty Panel in place to select the most promising proposals in January 2023.
Jane Kendrew – Director of Translational Oncology at Sygnature Discovery – will be representing the company as part of this expert panel, providing review in consultation with her Sygnature colleagues from specialist areas, including DMPK, in vivo pharmacology, chemistry and bioscience.
Jane comments: “The level of innovative drug discovery ongoing in the UK is exceptional. I am excited to be able to contribute to this in a small way through my involvement as an expert panellist in ODP2.”
Overview of the second Oncology Development Programme
ODP2 consists of three parts, as follows:
- The fully immersive one-day masterclass and an opportunity to hear how innovations are assessed by pharma
- A three-day deep dive into the highly successful Lean Life Science approach to developing oncology assets and securing investment, which is also an opportunity to engage directly with pharma and CRO experts.
- By application, selected participants work closely with the partners to create and validate the integrated plans necessary to ensure successful development and attract potential funding.
Delivered by a unique team of seasoned oncology R&D professionals, commercial, and investment specialists, ODP2 aims to identify, de-risk and catalyse commercially viable UK-based innovations to improve diagnosis and treatment of cancer, as well as to accelerate the translation of emerging cancer research for patient benefit.
About Sygnature Discovery
Sygnature Discovery is a leading CRO which works extensively in the field of oncology drug discovery. The company focuses on delivering integrated drug discovery projects through co-located, interdisciplinary teams of highly trained specialists and has a proven track record of success, with twenty-one drug discovery projects having progressed into clinical trials (Phases I, II and III) in the last 11 years. Notable examples include STP938 – the world’s most advanced investigational CTPS1 inhibitor to treat relapsed/refractory B or T cell lymphoma, which was recently dosed in a phase 1/2 trial.